| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-554 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate |
2003-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2005-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2005523255-A |
| titleOfInvention |
Use of benzothiazepine with activity as an inhibitor of ileal bile acid transport to reduce cholesterololemia |
| abstract |
Use of ileal bile acid transport (IBAT) inhibitors and IBAT inhibitors and HMG CoA reductase inhibitors in the treatment of warm-blooded animals such as humans with hypercholesterolemia and / or other forms of dyslipidemia The use of a combination is described, wherein said hypercholesterolemia and dyslipidemia are characterized by a deficiency in lipoproteins or their receptors. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20140032952-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013541584-A |
| priorityDate |
2002-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |